Clinical Gastroenterology and Hepatology, Год журнала: 2023, Номер 22(6), С. 1340 - 1340
Опубликована: Окт. 20, 2023
Язык: Английский
Liver International, Год журнала: 2025, Номер 45(3)
Опубликована: Фев. 10, 2025
Patient, clinician, and system-related barriers may affect adherence to hepatocellular carcinoma (HCC) surveillance programmes. The impact of a dedicated automated recall HCC programme on retention rates in patients eligible for screening is unknown. We aimed describe evaluate large publicly funded healthcare system. Data were collected from January 1, 2013, December 31, 2022, retrospective cohort subjects enrolled semi-annual as per the American Association Study Liver Disease guidance Calgary Health Zone (~1.6 million), Canada. Patients excluded if there was incomplete data or did not meet indications surveillance. Cox regression used identify predictors non-retention A total 7269 included. median age 55.5 years (IQR: 45.5-63.8), 60% male, 46% Asian descent, 51% had HBV infection, 36% cirrhosis (35% alcohol-related). Median follow-up 4.9 1.5-7.2). Overall, 52% (n = 3768) retained programme, while 8.3% 603) left potential medical reasons, 40% 2898) lost follow-up. time those 0.81 0.0-2.8) compared 6.75 5.6-8.6; p < 0.001). In multivariable analysis, HCV aetiology (HR 1.41; CI 1.23-1.62, 0.01), African ethnicity 1.20, 1.02-1.42, 0.03), 1.16, 1.05-1.28, 0.01) increased risk dropout. On interaction Hepatitis B amongst cirrhotic also dropout 1.48, 1.05-2.07, 0.02). has high rate multi-ethnic identifying certain marginalised patient populations, such with viral liver disease, cirrhosis, ethnicity, particularly vulnerable loss
Язык: Английский
Процитировано
1
JHEP Reports, Год журнала: 2025, Номер 7(5), С. 101357 - 101357
Опубликована: Фев. 13, 2025
Abbreviated MRI (AMRI) has been proposed as an alternative to ultrasound for hepatocellular carcinoma (HCC) surveillance; however, comparative data AMRI and are needed. Thus, we evaluated the sensitivity specificity of dynamic contrast-enhanced (DCE)-AMRI early-stage HCC detection in patients with cirrhosis. We conducted a multicenter retrospective case-control study among cirrhosis (cases per Milan Criteria; controls without HCC) who underwent DCE-MRI within 6-month period between 2012 2019. diagnosis was confirmed by imaging alone 85% histopathology 15% patients. Dynamic examinations were simulated from full selecting relevant sequences. Independent, blinded interpretations ultrasounds results performed using Liver Imaging Reporting Data System algorithms. Ultrasounds considered positive if US-3 observations detected. LR-4, LR-5, or LR-M Per-patient estimated, cross-modality differences tested. included 216 cases 432 controls. Patient-level significantly higher compared ultrasound: 80.1% (95% CI 76.1-83.6) vs. 71.1% 66.6-75.2), p <0.001, 91.9% 89.9-93.5) 72.3% 69.3-75.2), respectively. Child-Pugh B (80.8% 57.4%, <0.001) but not those A (84.7% 78.6%, = 0.07) C (52.6% 68.4%, 0.18). may be more sensitive specific ultrasound, although its relative benefit might smaller Larger direct sets needed, particularly surveillance strategies. is increasingly recognized surveillance. However, existing limited single-center samples, spectrum bias, lack ultrasound. found that had per-patient HCC, cirrhosis, both modalities underperformed If sufficiently validated, could adopted into practice guidelines serve preferred select subgroups
Язык: Английский
Процитировано
1
Hepatobiliary & pancreatic diseases international, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
1
Cancer Epidemiology Biomarkers & Prevention, Год журнала: 2024, Номер 33(4), С. 463 - 470
Опубликована: Янв. 22, 2024
Abstract Background: Racial and ethnic disparities in hepatocellular carcinoma (HCC) prognosis exist, partly related to differential failures along the cancer care continuum. We characterized racial treatment receipt among patients with HCC United States. Methods: searched Medline, Embase, CINAHL databases identify studies published between January 2012 March 2022 reporting adult HCC, stratified by race or ethnicity. calculated pooled odds ratios for using random effects models. Results: identified 15 320,686 (65.8% White, 13.9% Black, 10.4% Asian, 8.5% Hispanic). Overall, 33.2% of underwent any treatment, 22.7% curative treatment. Compared White patients, Black had lower (OR 0.67, 95% CI 0.55–0.81) 0.74, 0.71–0.78). Similarly, Hispanic 0.79, 0.73–0.84). Conclusions: There were significant receipt, having receiving while Impact: differences serve as an intervention target reduce prognosis.
Язык: Английский
Процитировано
8
Talanta, Год журнала: 2025, Номер 287, С. 127694 - 127694
Опубликована: Фев. 4, 2025
Язык: Английский
Процитировано
0
Expert Review of Anticancer Therapy, Год журнала: 2025, Номер unknown
Опубликована: Фев. 12, 2025
Introduction Prognosis in patients with HCC is largely determined by stage at diagnosis, highlighting the importance of effective early detection strategies. surveillance associated increased and reduced HCC-related mortality currently recommended cirrhosis or chronic HBV infection.
Язык: Английский
Процитировано
0
European Radiology, Год журнала: 2025, Номер unknown
Опубликована: Март 20, 2025
Язык: Английский
Процитировано
0
Frontiers in Medicine, Год журнала: 2025, Номер 12
Опубликована: Апрель 2, 2025
DNA methylation carrying epigenetic aberrations could potentially serve as a non-invasive tool for revolutionizing cancer diagnosis and monitoring. Here, we comprehensively evaluated the diagnostic value of plasma methylated HIST1H3G, constructed prognostic models aimed at facilitating early detection improving prognosis hepatocellular carcinoma (HCC). The level HIST1H3G promoter in HCC tissues was based on UALCAN database, followed by validation through serum samples collected from patients. We recruited 205 participants, encompassing 70 patients, 79 liver cirrhosis (LC) 46 hepatitis patients 10 before after treatment with either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Analysis performed using methylation-specific quantitative polymerase chain reaction (qPCR). Diagnostic prediction were formulated random forest algorithm, performance these rigorously receiver operating characteristics curve (ROC) analysis. markedly elevated both derived PIVKA-II, total bilirubin (TBIL) age selected optimal markers included development model. This model demonstrated superior accuracy distinguishing high-risk populations, outperforming alpha-fetoprotein (AFP) training cohort consisting LC comprising Additionally, albumin (Alb) chosen to establish diagnosis, this exhibited remarkable ability identify HCC. Furthermore, our proved effective predicting survival outcomes Together, identified validated that incorporated clinically applicable serological indicators findings study established pivotal foundation approach identification management
Язык: Английский
Процитировано
0
Scientific Reports, Год журнала: 2024, Номер 14(1)
Опубликована: Авг. 9, 2024
Hepatocellular carcinoma (HCC) is the most common liver cancer and among leading causes of cancer-related death worldwide. There no reliable biomarker for early diagnosis HCC. Circulating microRNAs (miRNAs) have attracted attention as potential biomarkers disease. By small-RNA next-generation sequencing, analysis serum miRNAs led to identification molecular signatures able discriminate advanced HCC from (n = 246); CIRRHOSIS 299); HEALTHY 320); 343); 414). Cirrhotic patients exhibited similar miRNA profiles, yet a small number 57) were distinguish these two classes patients. A second objective study was identify capable predicting response therapy in with All treated sorafenib first-line therapy: 24 nonresponsive responsive. Analysis circulating revealed 54 signature separate subgroups. This suggested that could be useful monitoring diseases ranging cirrhosis possibly susceptibility treatment based on sorafenib.
Язык: Английский
Процитировано
3
JNCI Journal of the National Cancer Institute, Год журнала: 2024, Номер unknown
Опубликована: Сен. 17, 2024
Abstract Background The value of hepatocellular carcinoma screening is defined by the balance benefits from early tumor detection vs harms because false-positive results. We evaluated a mailed outreach strategy for in patients with cirrhosis. Methods conducted multicenter pragmatic randomized clinical trial comparing (n = 1436) and usual care visit-based among cirrhosis at 3 health systems March 2018 to September 2021. Outcomes interest were stage (ie, benefit) diagnostic evaluation or indeterminate results harm). Screening harm was categorized as mild, moderate, severe based on number type exams. All included intention-to-screen analyses. Results Of 125 diagnosed (67 58 care), 71.2% found an per Milan criteria. Early did not statistically significantly differ between arms (64.2% 79.3%; P .06). proportion physical also (10.8% 10.7%; .95) 5.9% both having mild harms; 4.0% 3.8%, respectively, moderate 0.9% 1.0%, harms. Conclusion Most enrolled detected stage, minority experienced A increase compared care. Clinical trials NCT02582918 NCT03756051.
Язык: Английский
Процитировано
2